AWD 12171

Drug Profile

AWD 12171

Latest Information Update: 23 Aug 2007

Price : $50

At a glance

  • Originator elbion
  • Class
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Erectile dysfunction

Most Recent Events

  • 02 Sep 2005 No development reported - Preclinical for Erectile dysfunction in Germany (unspecified route)
  • 13 Mar 2002 AWD 12171 is available for licensing
  • 07 Feb 2000 Preclinical development for Erectile dysfunction in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top